Treat with confidence. Trusted answers from the American Academy of Pediatrics. The 2015 Childhood Immunization Schedule H. Cody Meissner, MD, FAAP Floating Hospital for Children Tufts University School of Medicine

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Disclaimers  Statements and opinions expressed are those of the author and not necessarily those of the American Academy of Pediatrics (AAP).  I have no financial relationship with the manufacturer(s) of any commercial product(s) discussed in this presentation.  I may discuss the use of vaccines in a manner that is not consistent with the Package Insert, but all recommendations are in accordance with recommendations from the Advisory Committee on Immunization Practices (ACIP) and the AAP.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Title  Text

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Week ending February 7, 2015 Influenza Positive Tests Reported to Centers for Disease Control and Prevention (CDC) by US World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) Collaborating Laboratories, National Summary, 2014–2015

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Total, Flu LAIV, Flu Live Attenuated Influenza Vaccine (LAIV) Effectiveness against Medically-attended Influenza among 2–18 Year Olds, US Flu Vaccine Effectiveness (VE) Network

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Summary: US Flu VE Network  During 2011–2012 and 2012–2013, there was no statistically significant difference in relative efficacy of LAIV versus inactivated influenza vaccine (IIV).  During 2013–2014, there was no statistically significant efficacy among LAIV recipients. Efficacy of IIV was statistically significant.  H1N1pdm09 was the predominant virus during 2013–2014. o Subtype analysis is consistent with lack of activity for LAIV against H1N1pdm09. o Cannot rule out specific issue related to 2013–2014, e.g. study enrollees or design, unmeasured confounding or vaccine issue.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Licensed Human Papillomavirus (HPV) Vaccines L1 – Major capsid protein; VLP – virus like particle

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Adolescent Vaccination Coverage United States, 2006–2013 Elam-Evans LD, Yankey D, Jeyarajah J. National, regional, state and selected local area vaccination coverage among adolescents aged 13–17 years—United States, MMWR. 2014;63(29);625–633.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Courtesy of H. Cody Meissner, MD, FAAP Measles Cases in the United States

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Measles Cases in the United States, 1994–2014 Orenstein W, Seib K. Mounting a good offense against measles. N Engl J Med. 2014;371(18):1661–1663.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Recommendations for Healthcare Providers  Ensure all people are up to date on the measles, mumps, and rubella (MMR) vaccine.  All travelers ≥6 months must be protected from measles.  Consider measles in anyone with a febrile rash illness and cough, coryza, conjunctivitis in anyone who has recently traveled or who has had contact with someone with a febrile rash illness.  The incubation period for measles, from exposure to fever, is about 10 days (range: 7 to 12 days).  Isolate suspected measles case and immediately report to local health department.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Surface Antigens, N. meningitidis Serruto D, Bottomley MJ, Ram S. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2011–2012;30 (Suppl 3):B87–B97.

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Two Meningococcal Serogroup B Vaccines  4CMenB (Bexsero, Novartis) o Licensed by the Food and Drug Administration (FDA) in January 2015 for a 2-dose schedule o Genome derived Neisseria antigens (reverse vaccinology) o Used under a CDC sponsored investigational new drug at Princeton and University of California Santa Barbara in December 2013; approximately 30,000 doses administered March 2014: One death in Drexel student; no recommendation for vaccine use at this time o Multivalent vaccine (MenABCWY), phase II trials  Bivalent MenB (Trumenba, Pfizer) o Licensed by FDA in October 2014 for a 3-dose schedule o Two highly conserved variants of factor H binding protein (fHbp) o Multivalent vaccine (MenABCWY), phase III trials

Treat with confidence. Trusted answers from the American Academy of Pediatrics. Visit Pediatric Care Online today for additional information on this and other topics. Pediatric Care Online is a convenient electronic resource for immediate expert help with virtually every pediatric clinical information need with must-have resources that are included in a comprehensive reference library and time-saving clinical tools.